Novozymes诺维信品牌怎么样 申请店铺

诺维信公司是全球工业酶制剂和微生物制剂的主导企业，拥有超过40%的世界市场份额。2001年，诺维信公司从丹麦著名的制药公司诺和诺德公司分离出来；2004年，诺维信公司全球销售收入达到10亿美金，业务遍及130个国家。迄今为止，诺维信已经连续五年名列道琼斯可持续发展指数全球和欧洲医药/生物技术板块企业可持续发展第一名。诺维信拥有4,000多项有效专利、正在申请的专利和专利许可。在研发工作中，诺维信运用了传统微生物学、现代生物化学和分子生物学领域的多项先进核心技术，包括表达克隆、重组技术、蛋白工程和高通量筛选技术等，力争为广大客户提供所需的各种酶类。

诺维信是丹麦在华最大投资企业之一，自1994年起累计投资2亿美元，在天津经济技术开发区建立了全球酶制剂生产基地，在北京中关村科技园区设立了中国首家外资生物技术研发中心。此外，诺维信在江苏太仓建立了苏州宏达制酶有限公司；在沈阳设立了微生物生产基地；销售网络遍及全国。

中国在诺维信全球化战略中占有举足轻重的地位，已逐渐成为诺维信最重要的业务增长引擎和研发、生产及运营中心。为了更接近蓬勃发展的中国市场，以更灵活高效的方式满足中国客户的多样化需求，诺维信正在将越来越多的功能和业务重心转移到中国，并在本地广纳贤士。

在中国，诺维信秉承经营业绩、环境表现和社会责任并举的“三重底线”，积极研发适合本地市场的新产品和新应用，解决中国工业和工艺所面临的问题；同时投身地方环保事业，支持大学环境与生命科学研究及教育，倡导和推动生态工业与循环经济，立志成为中国最佳生物解决方案提供商和可持续发展的战略伙伴。

Novozyme is the leading enterprise of industrial enzyme preparation and microbial preparation in the world, with more than 40% of the world market share. In 2001, Novozymes was separated from Novo Nordisk, a famous pharmaceutical company in Denmark. In 2004, Novozymes's global sales revenue reached US $1 billion, with businesses in 130 countries. So far, Novozymes has ranked first in the world of Dow Jones sustainable development index and in the sustainable development of European pharmaceutical / biotechnology companies for five consecutive years. Novozymes has more than 4000 valid patents, patent applications and patent licenses. In the R & D work, novozyme has applied a number of advanced core technologies in the fields of traditional microbiology, modern biochemistry and molecular biology, including expression cloning, recombination technology, protein engineering and high-throughput screening technology, striving to provide customers with all kinds of enzymes they need. Novozymes is one of the largest Danish investment enterprises in China. Since 1994, Novozymes has invested 200 million US dollars in total. It has established a global enzyme production base in Tianjin Economic and Technological Development Zone and the first foreign-funded biotechnology research and development center in China in Zhongguancun Science and Technology Park, Beijing. In addition, novozyme has established Suzhou Hongda enzyme Manufacturing Co., Ltd. in Taicang, Jiangsu Province; established a microbial production base in Shenyang; and has a sales network throughout the country. China plays an important role in novozyme's global strategy and has gradually become the most important business growth engine and R & D, production and operation center of novozyme. In order to get closer to the booming Chinese market and meet the diversified needs of Chinese customers in a more flexible and efficient way, novozyme is transferring more and more functions and business focus to China and attracting talents locally. In China, Novozymes adheres to the "triple bottom line" of business performance, environmental performance and social responsibility, actively develops new products and applications suitable for the local market, and solves the problems faced by Chinese industry and technology; at the same time, Novozymes devotes itself to the local environmental protection, supports the research and education of university environment and life science, advocates and promotes the ecological industry and circular economy, and aspires to become China China's best biological solution provider and strategic partner for sustainable development.

本文链接： https://brand.waitui.com/6af0c06dc.html 联系电话：02225322062